Powering insightful data-driven discoveries

“Through our partnership with Diversigen, we are converting finite biosamples into reusable assets that will enable researchers across the country to not only gain expedited access to molecular data, but also leverage uniform datasets across projects, ultimately generating a critical mass of information necessary to advance the science.”

“[Diversigen] has been a valuable corporate collaborator in our studies of the human microbiome delivering high-quality, genomic data in a timely manner. I’ve appreciated their responsiveness and willingness to work with Seres Health on meeting our various genomic characterization needs and look forward to continuing to work with [Diversigen] to support our future sequencing efforts.”

“[Diversigen’s] DNA sequencing platform and innovative bioinformatics methods for data analysis will be critical for development of the LifeKit® Prevent test. Prescient Metabiomics will leverage [Diversigen’s] discovery platform to accelerate development and validation through the FDA’s Breakthrough Devices Program.”

“Clinical studies of RBX2660 have demonstrated its potential to prevent recurrent C. diff infection, and early progress with RBX7455 has also been promising. Now, through our collaboration with [Diversigen] and its BoosterShot® technology, we can demonstrate how our drug platform rehabilitates a dysbiotic human microbiome,”